José Valdez Ramalho Madruga

Evolocumab in HIV-Infected Patients With Dyslipidemia

Paul D. Thompson, S. Trottier, C. Fichtenbaum, 2020, Journal of the American College of Cardiology.

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

A. Lazzarin, Jinrong Zhao, R. Leavitt, 2010, Journal of acquired immune deficiency syndromes.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

A. Borobia, H. Schuitemaker, Andrew Gibson, 2022, The Lancet Infectious Diseases.

Evolocumab Use in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-blind BEIJERINCK Study.

S. Trottier, C. Fichtenbaum, C. Katlama, 2020, Journal of the American College of Cardiology.